MedCity News

OCTOBER 15, 2023

The FDA’s digital health advisory committee will discuss technologies such as artificial intelligence and machine learning, virtual reality, and digital therapeutics as well as topics like decentralized clinical trials and patient-generated health data. Committee member nominations are due in December.

FDA 135

FDA Patients Biopharma 135

PharmaVoice

SEPTEMBER 22, 2023

Despite lower-than-expected demand for a competing treatment, DBV’s chief medical officer says the company’s topical skin patch could be a game-changing option for patients.

FDA 122

FDA Medical Patients 122

MedCity News

APRIL 27, 2023

Through a new partnership, Hopper Health’s providers and peer navigators will receive a personalized training plan from Violet that will help the clinicians and navigators understand how to provide inclusive care for patients of color and LGBTQ+ communities.

Training 116

Training Patients 116

pharmaphorum

OCTOBER 26, 2022

Topicals — creams, ointments, foams, and lotions applied directly to the affected areas of the skin — don’t get nearly as much TV time as their systemic biologic counterparts, the self-injectables with catchy theme songs, where the smiley and sleeveless walk confidently down the street and/or swim. How to quantify severity.

Side effects 94

Side effects Food and Drug Administration Patients Management 94

Pharmaceutical Technology

JULY 19, 2022

as a topical treatment of nonsegmental vitiligo in adults and paediatric patients aged 12 years and above. Opzelura is a topical formulation of a Janus kinase (JAK) inhibitor. With the latest development, Opzelura has became the first treatment for repigmentation in patients with vitiligo to receive FDA approval.

Food and Drug Administration 116

Food and Drug Administration FDA Food Safety 116

Impetus Digital

APRIL 22, 2024

Back by Popular Demand: Virtual Patient Engagement Programs About the webinar Join our exclusive small-group webinars to dive deep into the best practices of virtual patient engagement. Learn from our expert speakers about the most effective strategies for insight-gathering, patient support, and educational initiatives.

Patients 52

Patients Education Professional Services Healthcare Provider 52

PM360

OCTOBER 27, 2022

a clinical-stage biopharmaceutical company focused on gene therapies for dermatological diseases, recently announced positive results from a Phase 3 clinical trial on its investigational compound Beremagene Geperpavec (B-VEC), a topical gene therapy designed to treat the debilitating skin condition dystrophic epidermolysis bullosa (DEB).

Safety 104

Safety Patients FDA Medical 104

MedCity News

AUGUST 1, 2022

The FDA approved Arcutis Biotherapeutics drug Zoryve, a topical treatment for plaque psoriasis. With the decision, the company will proceed with a pricing strategy it believes will speed up insurance coverage and patient adoption of the new treatment for the chronic inflammatory skin disorder.

Insurance 112

Insurance FDA Patients Biopharma 112

Pharmaceutical Technology

MAY 26, 2023

Krystal Biotech has received approval from the US Food and Drug Administration for topical gene therapy VYJUVEK to treat dystrophic epidermolysis bullosa (DEB) in adults and in children aged six months and above. Patients with DEB have extremely fragile skin that blisters and tears with minor trauma or friction such as scratching or rubbing.

Food and Drug Administration 105

Food and Drug Administration FDA Manufacturing Food 105

European Pharmaceutical Review

NOVEMBER 17, 2023

The European Commission has approved Ebglyss (lebrikizumab) for atopic dermatitis patients 12 years and older with a body weight of at least 40kg, who are candidates for systemic therapy. The Phase III clinical development programme, which involved some 1,300 patients, also evaluated the safety profile of lebrikizumab.

Safety 88

Safety Patients Management Leads 88

World of DTC Marketing

AUGUST 10, 2022

Time and time again, I’ve found, in research talking with patients, that they want a lot more information before they ask for a new drug. They’re using label and FDA-friendly language, which isn’t what patients want to hear. Instead, patients are going online and spreading inaccurate information.

Marketing 252

Marketing Media Side effects Pharma 252

PharmExec

DECEMBER 19, 2023

Indication of Adbry (tralokinumab-ldrm) expanded to include patients 12 to 17 years of age with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or for whom those therapies are not advisable.

Patients 52

Patients Prescription Pharma FDA 52

PM360

NOVEMBER 27, 2023

Continuing medical education (CME) is a top priority for healthcare providers in order to maintain their medical licensure, broaden and update their clinical knowledge, hone their skills, feed their curiosity, and ensure patients receive the best care and outcomes. The traditional development of CME materials is almost all done by humans.

Education 105

Education Medical Training Healthcare 105

Pharmaceutical Technology

MAY 2, 2023

Soligenix has signed an exclusive option agreement with Silk Road Therapeutics for the right to acquire Pentoxifylline (PTX) topical formulation intended to treat mucocutaneous ulcers in Behçet’s disease (BD) patients. Patients applied the PTX mucoadhesive gel four times a day for up to 14 days for treating current mouth ulcers.

Safety 52

Safety Physicians Patients Management 52

PM360

APRIL 22, 2024

Leveraging the power of social media influencers either through patients, caregivers, or HCPs, pharmaceutical companies are navigating novel ways to communicate with potential consumers and prescribers. Sensitivity and Empathy Navigating the intricacies of healthcare topics requires a delicate balance of sensitivity and empathy.

Media 52

Media Healthcare Healthcare Ethics 52

PharmExec

AUGUST 1, 2023

Patient centricity is an imperative focus for the advancement of life sciences businesses, and Sharon Suchotliff from ZS delves into this topic by sharing her keen insights.

Patients 52

Patients 52

Authentic Influence Group

AUGUST 26, 2021

This was such a unique topic to cover. If the physician walks in and really takes a moment to look at the patient, make some eye contact, be open, also be front-facing … that's going to make a big difference in opening up that trust.” Building trust encourages more honesty from patients. A quick preview of what we discussed. “If

Doctors 130

Doctors Patients Physicians Consulting 130

Pharmaceutical Technology

JUNE 8, 2023

DTx Pharma co-founder and CEO Artie Suckow stated: “Patients living with CMT1A are in urgent need of treatment and this represents a significant step forward for the patients and the DTx team as we advance DTx-1252 toward the clinic. An estimated 150,000 patients in Europe and the US are living with CMT1A.

Food and Drug Administration 98

Food and Drug Administration FDA Food Manufacturing 98

World of DTC Marketing

DECEMBER 28, 2020

First, let’s dispel a recent topic: telehealth. Yes, telehealth has grown substantially, but that’s because patients are afraid of going into doctor’s offices. However, that being said, patients will use telehealth for tasks “they feel” don’t require an in-person visit.

Doctors 296

Doctors Side effects Marketing Electronics 296

PharmaTech

MAY 25, 2023

FDA has approved the first topical gene therapy product for treating wounds in patients with dystrophic epidermolysis bullosa.

FDA 52

FDA Patients 52

pharmaphorum

NOVEMBER 15, 2022

Then we’ll hear from Aptar Digital Health’s Sai Shankar and Pierre Laurent in a session all about patients as partners in healthcare. The day will continue with other hot topics for pharma, including health equity, cell and gene therapy, oncology, and pharmacy model disruption. Cheryl Pegus & SCAN Health Plan’s Dr. Sachin Jain.

Pharma 114

Pharma Healthcare Healthcare Medical 114

Pharmaceutical Technology

DECEMBER 5, 2022

Incyte could also grant a potential licence to CMS for other topical formulations of ruxolitinib to treat ailments, such as vitiligo and atopic dermatitis, in the future, for patients in mainland China, Hong Kong, Macau, Taiwan and some Southeast Asia nations.

Food and Drug Administration 52

Food and Drug Administration Healthcare Provider Food Patients 52

pharmaphorum

JULY 19, 2022

The FDA’s decision to clear the new indication for the topical JAK1/JAK2 inhibitor came after a priority review that was delayed by a request for additional data by the regulator, holding back a decision by three months. million people in the US. The company is gunning for sales in atopic dermatitis alone of $1.5

FDA 94

FDA Side effects Sales Safety 94

Healthcare Success

MARCH 13, 2023

The new E stands for “experience,” and here’s what this means for your business: Experience, Expertise, Authoritativeness, and Trust (E-E-A-T) Google defines experience as “first-hand or life experience for the topic.” A website or content creator who is the uniquely authoritative, go-to source for a topic has very high E-E-A-T.

Healthcare 61

Healthcare Healthcare Media Physicians 61

Pharmaceutical Technology

APRIL 19, 2023

to treat patients aged nine years and above with seborrheic dermatitis. If approved, roflumilast foam would be the first topical drug with a new mechanism of action for this condition in over two decades, highlighting the unique formulation and deep dermatological expertise that Arcutis brings to immuno-dermatology.”

Food and Drug Administration 52

Food and Drug Administration FDA Safety Prescription 52

PharmExec

JANUARY 11, 2023

Exploring the most relevant topics affecting the biopharma industry as the new year gets underway—ranging from trends ripe with risk and opportunity to those driving more definitive growth opportunities in patient care.

Biopharma 52

Biopharma Patients 52

Pharmaceutical Technology

JUNE 9, 2023

It has been designed to address the unmet needs of patients and to provide quick action and well-tolerated dry eye drug therapy. CyclASol is topical anti-inflammatory and immunomodulating ophthalmic drug solution containing 0.1%

Food and Drug Administration 98

Food and Drug Administration FDA Medical science Food 98

Pharmaceutical Technology

MAY 22, 2023

The US Food and Drug Administration (FDA) has granted approval for Krystal Biotech’s Vyjuvek (beremagene geperpavec-svdt) to treat dystrophic epidermolysis bullosa (DEB) in patients aged six months and above. Vyjuvek is a non-invasive, topical, re-dosable gene therapy that delivers functional human COL7A1 gene copies to offer wound healing.

FDA 52

FDA Food and Drug Administration Patients Food 52

European Pharmaceutical Review

AUGUST 24, 2022

The topic of bacterial endotoxin testing (BET), while a unique requirement for the pharmaceutical industry, has far?reaching 4-7 Here, the approach taken at AstraZeneca to optimise test methodology to provide assurance of patient safety, reduce the burden on a natural resource and continue to improve in this area is shared.

Safety 90

Safety Pharmaceutical Management Patients 90

PM360

MARCH 19, 2024

While everyone was talking about the transformative power of data and AI, the healthcare track repeatedly brought the conversation back to what matters most: patients. Patients were the lens through which all innovation was filtered, and rightly so. Patients must remain the impetus and North Star for the industry’s use of technology.

Healthcare 52

Healthcare Healthcare Pharmacology Medicine 52

pharmaphorum

OCTOBER 6, 2022

The new version – dubbed Florence 2.0 – covers a broader range of topics. The topics chosen for Florence are some of those that have the greatest burden on health around the world, and according to her developers she could help support healthcare workers in areas where there are shortages in healthcare staff.

Healthcare 136

Healthcare Healthcare Leads Patients 136

PM360

APRIL 22, 2024

Patient profiles can help healthcare professionals understand their patients better based on their personal issues, thus helping them feel more confident and comfortable with their treatment experience. They usually focus on physical characteristics that can help doctors identify these patients.

Patients 52

Patients Education Healthcare Healthcare 52

LEVO Health

SEPTEMBER 15, 2023

Patient testimonials have always been a cornerstone of trust in the healthcare industry. Patient testimonial videos not only humanize the healthcare experience but also provide potential patients with relatable stories that can influence their healthcare decisions. Crafting a Compelling Patient Testimonial Video: Step-by-Step 1.

Patients 52

Patients Distribution Healthcare Healthcare 52

PM360

APRIL 22, 2024

Think: KOL videos that take less than 5 minutes to watch, or a podcast series with short episodes breaking down one complicated topic. Opt for programs that allow HCPs to co-create educational content from messaging and image options that are more likely to resonate with their patients’ unique challenges and needs.

Physicians 52

Physicians Education Healthcare Healthcare 52

Pharma Leaders

MAY 15, 2023

Manufacturers of amphetamine and methylphenidate products, a class of stimulant medications used to treat ADHD and other disorders, must update their labeling and prescribing information to “clearly inform” patients, caregivers and healthcare professionals risks associated with these medications. Related Topics

Medical 52

Medical FDA Prescription Manufacturing 52

MedCity News

JUNE 15, 2023

But while hospice may be a newer topic of discussion for some, those of us who work to provide this type of health care have long understood the positive impact it has on patients, families and the health care system. The NORC study reaffirms the value of hospice care in patient and family satisfaction at the end of life.

Specialization 109

Specialization Healthcare Healthcare Patients 109

European Pharmaceutical Review

FEBRUARY 24, 2023

About ruxolitinib cream Ruxolitinib cream is a novel cream formulation of Incyte’s selective Janus kinase (JAK)1/JAK2 inhibitor ruxolitinib, approved by the US Food & Drug Administration (FDA) for topical treatment of nonsegmental vitiligo in patients 12 years of age and older. A higher proportion of patients responded at Week 521.

Food and Drug Administration 102

Food and Drug Administration Medicine Medical Food 102